Navigation Links
NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
Date:5/8/2008

escription of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties, relative to the proposed acquisition, include, but are not limited to: the risk that the parties may not consummate the transaction in the expected timeframe or that intervening factors may cause the parties to alter the terms (financial or otherwise) of the transaction; the risk that NuVasive may not be able to achieve expected synergies and strategic benefits from Osteocel or the acquired technology; the risk that NuVasive will not be able to successfully integrate the acquired operations; the risk that revenues or profits following the transaction will be lower than expected; the risk that business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) is greater than expected following the transaction; and the risk that NuVasive will not be able to acquire or produce a sufficient supply of product following the transaction. Additionally, other factors that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasi
'/>"/>
SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
2. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
3. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
4. NuVasive to Host Investor Reception on September 11, 2007
5. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
6. Quintiles Signs Agreement to Acquire Eidetics
7. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
8. Assay Designs(TM) Announces Collaboration with Medical University of South Carolina (MUSC)
9. Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation
10. DelSite Signs Technology Evaluation Agreement With Global Pharmaceutical Company for GelSite(R) Polymer
11. Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Brook, NY (PRWEB) August 01, 2014 ... @APDN), a provider of DNA-based anti-counterfeiting technology and product ... August 12, 2014 to discuss its fiscal third quarter ... filed with the SEC by the end of the ... DNA Sciences, Inc. management will host a conference call ...
(Date:8/1/2014)... AACC, a global scientific and medical professional ... an updated brand identity today that reflects the organization,s ... healthcare environment and continue to do what they do ... the care they need. " The ... essential role in saving lives and making people healthier," ...
(Date:8/1/2014)... Toronto, Canada (PRWEB) August 01, 2014 ... what should it cost? This webinar will discuss how ... construction. , Join speakers Bob Allen, Senior Director ... Director of Process Engineering at Fluor Industrial Services, and ... supporting Manufacturing Asset Planning at Amgen, as they provide ...
(Date:7/31/2014)... 2014 Food and natural product ... for food alternatives that offer variety, as well ... ingredient market has numerous players operating in the ... Force Technology (VFT). VFT is a science-driven ... patterns, all tested to produce stable, effective and ...
Breaking Biology Technology:Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3AACC Debuts Refreshed Brand Identity 2Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2
... importance on ... indication-specific FDA approval, WALTHAM, Mass., April 2, 2008 ... into the marketing of biliary,stents for off-label uses in the ... could become a key focus for,stent manufacturers. A recent study ...
... 25 Global Pharmaceutical Companies Select Drug ... MOUNTAIN VIEW, Calif., April 2, 2008 ,Pharsight ... of software,strategic consulting, and regulatory services for optimizing ... global pharmaceutical,companies have become customers for its Drug ...
... Nutritional Distributor in Greece, to Purchase an Aggregate ... of Over $200,000 of Resurgex(R) in 2008, ... a wholly owned subsidiary of Millennium,Biotechnologies Group, Inc. (OTC Bulletin ... purchase order for the international,distribution of the Resurgex(R) line in ...
Cached Biology Technology:Off-Label Stent Use: How Important Are FDA Approvals to Physicians? 2Pharsight Signs Two New DMX(R) License Customers 2Pharsight Signs Two New DMX(R) License Customers 3Millennium Announces $200,000 Purchase Order From Greek Distributor 2Millennium Announces $200,000 Purchase Order From Greek Distributor 3
(Date:7/31/2014)... Researchers who studied 100 twin pairs have identified a ... on less than six hours of sleep per night. ... the effects of sleep deprivation. , Results show that a ... had an average nightly sleep duration of only five ... non-carrier twin, who slept for about six hours and five ...
(Date:7/31/2014)... in German . ... similar to a sponge that soaks up liquids. Hence, ... or greenhouse gases. However, loading of many MOFs is ... (KIT) now report in Nature Communications that ... surface. This can be prevented by water-free synthesis and ...
(Date:7/31/2014)... has been made to help better identify and treat those ... narrowing and enlarging of medium sized arteries in the body, ... organs causing damage. In a new report appearing in August ... scientists provide evidence that that FMD may not be limited ... a connection to abnormalities of bones and joints, as well ...
Breaking Biology News(10 mins):Study of twins discovers gene mutation linked to short sleep duration 2Free pores for molecule transport 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... Scientists at the University of Idaho currently are involved ... been running rampant for the past decade. But the killer,s ... Instead, it,s on the minds of ecologists on every continent ... (Bd). It is a "chytrid" fungus that lives on ...
... to slam the Gulf Coast, and even reason to believe ... How we handle them will be the primary topic of ... Global Climate Impact in the Gulf Coast Conference Oct. 29-31. ... and Evacuation from Disaster Center, primary sponsor of the conference. ...
... 2008Three years after Hurricane Katrina devastated New Orleans, people ... city,s floodwall system. A new article in the fall ... 3) suggests that Formosan subterranean termites played a large ... Louisiana State University AgCenter, discovered Formosan subterranean termites (Coptotermes ...
Cached Biology News:Modern genetics vs. ancient frog-killing fungus 2Modern genetics vs. ancient frog-killing fungus 3Weather woes emphasize need for SSPEED 2Did termites help Katrina destroy New Orleans floodwalls? 2
Certified U.S. origin. Bovine Serum:, *Certified U.S. origin. Available raw, nonsterile filtered, or sterile filtered. , , *Sterility tested , , *Low Hemoglobin levels , , *Mycoplasma testing upon...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... contains 4 deuterium atoms at the 9, 10, ... use as an internal standard for the quantification ... is produced by the lipoxygenation of linoleic acid ... detected in atherosclerotic plaques, as an esterified component ...
Biology Products: